CRISPR Therapeutics
At close: Aug 8
PreMarket: 4:00PM EDT
Day High/Low- - -
52 Week High/Low42.51 - 86.95
Open / Close- / -
Float / Outstanding66.8M / 77.5M
Vol / Avg.0.2K / 2M
Mkt Cap6.3B
50d Avg. Price71.01
Div / Yield-
Payout Ratio-
Total Float66.8M

CRISPR Therapeutics (NASDAQ:CRSP), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1


Highest Price Target1


Lowest Price Target1


Consensus Price Target1


Analyst Rating Summary1


Analyst Firms Making Recommendations1

  • SVB Leerink
  • Citigroup
  • Oppenheimer
  • Evercore ISI Group
  • Chardan Capital

1calculated from analyst ratings published within the last 6 months

Analyst Ratings for CRISPR Therapeutics

All Ratings (0)

Upgrades (0)

Downgrades (0)

Initiations (0)

Analyst Firm
Price Target Change
Rating Change
Previous / Current Rating
Get Alert

CRISPR Therapeutics Questions & Answers

What is the target price for CRISPR Therapeutics (CRSP)?

The latest price target for CRISPR Therapeutics (NASDAQ: CRSP) was reported by SVB Leerink on August 8, 2022. The analyst firm set a price target for $107.00 expecting CRSP to rise to within 12 months (a possible 31.47% upside). 29 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for CRISPR Therapeutics (CRSP)?

The latest analyst rating for CRISPR Therapeutics (NASDAQ: CRSP) was provided by SVB Leerink, and CRISPR Therapeutics maintained their outperform rating.

When is the next analyst rating going to be posted or updated for CRISPR Therapeutics (CRSP)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CRISPR Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CRISPR Therapeutics was filed on August 8, 2022 so you should expect the next rating to be made available sometime around August 8, 2023.

Is the Analyst Rating CRISPR Therapeutics (CRSP) correct?

While ratings are subjective and will change, the latest CRISPR Therapeutics (CRSP) rating was a maintained with a price target of $112.00 to $107.00. The current price CRISPR Therapeutics (CRSP) is trading at is $81.39, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.